The effect of intravitreal bevacizumab (Avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration
Ehud Rechtman1, Ingeborg Stalmans2, Joseph Glovinsky1, Christophe Breusegem2, Joseph Moisseiev1, Joachim Van Calster2, Alon Harris31Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Department of Ophthalm...
Enregistré dans:
Auteurs principaux: | Ehud Rechtman, Ingeborg Stalmans, Joseph Glovinsky, et al |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/6639e7b2bd77417e9cb3d44df874ab2b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?
par: Nicola G Ghazi, et autres
Publié: (2010) -
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
par: Sinapis C, et autres
Publié: (2011) -
Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma
par: Dimitrios Brouzas, et autres
Publié: (2009) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
par: Juan Carlos Mesa Gutiérrez, et autres
Publié: (2008) -
Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin®) for AMD followed by controlateral sympathetic ophthalmia
par: Dimitrios Brouzas, et autres
Publié: (2009)